CDK 4/6 inhibitors for the treatment of meningioma.

Autor:	Young JS; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States., Kidwell RL; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States., Zheng A; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States., Haddad AF; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States., Aghi MK; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States., Raleigh DR; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States.; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, United States., Schulte JD; Division of Neuro-Oncology, University of California San Diego, San Diego, CA, United States.; Department of Neuroscience, University of California San Diego, San Diego, CA, United States., Butowski NA; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States.; Division of Neuro-Oncology, University of California San Francisco, San Francisco, CA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Jul 22; Vol. 12, pp. 931371. Date of Electronic Publication: 2022 Jul 22 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.931371
Abstrakt:	Meningiomas are the most common non-metastatic brain tumors, and although the majority are relatively slow-growing and histologically benign, a subset of meningiomas are aggressive and remain challenging to treat. Despite a standard of care that includes surgical resection and radiotherapy, and recent advances in meningioma molecular grouping, there are no systemic medical options for patients with meningiomas that are resistant to standard interventions. Misactivation of the cell cycle at the level of CDK4/6 is common in high-grade or molecularly aggressive meningiomas, and CDK4/6 has emerged as a potential target for systemic meningioma treatments. In this review, we describe the preclinical evidence for CDK4/6 inhibitors as a treatment for high-grade meningiomas and summarize evolving clinical experience with these agents. Further, we highlight upcoming clinical trials for patients meningiomas, and discuss future directions aimed at optimizing the efficacy of these therapies and selecting patients most likely to benefit from their use. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Young, Kidwell, Zheng, Haddad, Aghi, Raleigh, Schulte and Butowski.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu